placeholder
Importance
62
Trust
71
Urgency
30
SCIENCE
Semaglutide Beats Resmetirom in MASH Cost-Effectiveness - Medscape
A study shows semaglutide (a weight-loss and diabetes drug) costs less and works better than resmetirom for treating MASH, a serious liver disease. The findings may influence which drug doctors choose for patients.
Analysis
Novo's semaglutide may take MASH market share from Madrigal's resmetirom if doctors pick the cheaper, better option for liver disease patients.
- Study finds semaglutide more cost-effective than resmetirom for MASH
- Semaglutide showed better outcomes than resmetirom in the analysis
- Findings could shape doctor prescribing choices for MASH
Semaglutide News1mo
Read